INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said that a late-stage trial of a treatment for sarcoma did not meet the primary endpoints. It is suspending promotion of lartruvo. It expects ...
Original Article: Lilly: Phase 3 Soft Tissue Sarcoma Study Fails To Meet Primary Endpoints